WO2000008015A3 - Fsh mimetics for the treatment of infertility - Google Patents

Fsh mimetics for the treatment of infertility Download PDF

Info

Publication number
WO2000008015A3
WO2000008015A3 PCT/US1999/017755 US9917755W WO0008015A3 WO 2000008015 A3 WO2000008015 A3 WO 2000008015A3 US 9917755 W US9917755 W US 9917755W WO 0008015 A3 WO0008015 A3 WO 0008015A3
Authority
WO
WIPO (PCT)
Prior art keywords
infertility
treatment
fsh
derivatives
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/017755
Other languages
French (fr)
Other versions
WO2000008015A2 (en
Inventor
Tayer Nabil El
Adulla Reddy
David Buckler
Sharad Magar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Research Systems ARS Holding NV
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2000563648A priority Critical patent/JP4511042B2/en
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Priority to AT99939686T priority patent/ATE279407T1/en
Priority to DE69921147T priority patent/DE69921147T2/en
Priority to CA002339018A priority patent/CA2339018A1/en
Priority to DK99939686T priority patent/DK1102763T3/en
Priority to EP99939686A priority patent/EP1102763B1/en
Priority to AU53931/99A priority patent/AU772373B2/en
Priority to IL14106399A priority patent/IL141063A/en
Publication of WO2000008015A2 publication Critical patent/WO2000008015A2/en
Publication of WO2000008015A3 publication Critical patent/WO2000008015A3/en
Anticipated expiration legal-status Critical
Priority to AU2004202858A priority patent/AU2004202858B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides non-peptidic amino derivatives, their therapeutic use as well as pharmaceutical compositions that possess activity as Follicle Stimulating Hormone (FSH) agonists and are useful in the treatment of infertility. In particular, the invention provides cyclic and acyclic alpha- and beta-aminocarboxamides, more particularly tetrahydroisoquinolinecarboxamides, piperidinecarboxamides, pyrrolidinecarboxamides, and 2-amino-3-carboxamidopyridine derivatives.
PCT/US1999/017755 1998-08-07 1999-08-05 Fsh mimetics for the treatment of infertility Ceased WO2000008015A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL14106399A IL141063A (en) 1998-08-07 1999-08-05 Derivatives of pyrrolidine-2-carboxylic acid and piperidine-2-carboxylic acids and pharmaceutical compositions comprising said derivatives for treating infertility
AT99939686T ATE279407T1 (en) 1998-08-07 1999-08-05 FSH MIMETICS FOR THE TREATMENT OF INFERTILITY
DE69921147T DE69921147T2 (en) 1998-08-07 1999-08-05 FSH MIMETIKA FOR THE TREATMENT OF INFERTILITY
CA002339018A CA2339018A1 (en) 1998-08-07 1999-08-05 Fsh mimetics for the treatment of infertility
DK99939686T DK1102763T3 (en) 1999-08-05 1999-08-05 FSH mimetics for the treatment of infertility
JP2000563648A JP4511042B2 (en) 1998-08-07 1999-08-05 FSH mimics for the treatment of infertility
AU53931/99A AU772373B2 (en) 1998-08-07 1999-08-05 FSH mimetics for the treatment of infertility
EP99939686A EP1102763B1 (en) 1998-08-07 1999-08-05 Fsh mimetics for the treatment of infertility
AU2004202858A AU2004202858B2 (en) 1998-08-07 2004-06-25 FSH mimetics for the treatment of infertility

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9571298P 1998-08-07 1998-08-07
US60/095,712 1998-08-07

Publications (2)

Publication Number Publication Date
WO2000008015A2 WO2000008015A2 (en) 2000-02-17
WO2000008015A3 true WO2000008015A3 (en) 2000-05-11

Family

ID=22253270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017755 Ceased WO2000008015A2 (en) 1998-08-07 1999-08-05 Fsh mimetics for the treatment of infertility

Country Status (12)

Country Link
US (3) US6235755B1 (en)
EP (1) EP1102763B1 (en)
JP (1) JP4511042B2 (en)
AR (1) AR021755A1 (en)
AT (2) ATE279407T1 (en)
AU (1) AU772373B2 (en)
CA (1) CA2339018A1 (en)
DE (2) DE69931975T2 (en)
ES (2) ES2228084T3 (en)
IL (1) IL141063A (en)
PT (2) PT1102763E (en)
WO (1) WO2000008015A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071587B2 (en) 2009-05-27 2011-12-06 N. V. Organon (Dihydro)imidazoiso[5,1-A]quinolines

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025355A (en) 1997-05-19 2000-02-15 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
EP1156803A4 (en) 1999-02-09 2004-03-17 Bristol Myers Squibb Co LACTAM INHIBITORS OF FXa AND METHOD
AU2001256209B2 (en) * 2000-03-27 2006-02-16 Merck Serono Sa Pharmaceutically active pyrrolidine derivatives
ATE329899T1 (en) 2000-03-27 2006-07-15 Applied Research Systems PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
DE60201415T2 (en) * 2001-01-19 2006-02-09 Pharmacopeia, Inc. BISARYL DERIVATIVES WITH FSH RECEPTOR MODULATING ACTIVITY
US6900213B2 (en) 2001-01-19 2005-05-31 Pharmacopeia Drug Discovery, Inc. Bisaryl derivatives having FSH modulatory activity
PL364625A1 (en) 2001-02-23 2004-12-13 Merck & Co, Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
WO2002080928A1 (en) 2001-04-03 2002-10-17 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
IL158463A0 (en) 2001-05-05 2004-05-12 Smithkline Beecham Plc N-aroyl cyclic amines
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
US8058441B2 (en) * 2001-07-02 2011-11-15 N.V. Organon Tetrahydroquinoline derivatives
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds
ES2261740T3 (en) * 2001-10-22 2006-11-16 Applied Research Systems Ars Holding N.V. COMPOSITIONS OF FSH WITH HIGH DEGREE OF SIGNALING AND ITS USE FOR THE PREPARATION OF MEDICINES.
ES2399047T3 (en) * 2002-09-20 2013-03-25 Merck Serono Sa Piperazine derivatives and use procedure
CN100404508C (en) * 2002-12-20 2008-07-23 欧加农股份有限公司 Tetrahydroquinoline derivatives
TWI306855B (en) * 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
CN100386318C (en) * 2002-12-20 2008-05-07 欧加农股份有限公司 Tetrahydroquinoline derivatives and their use as FSH receptor modulators
TWI322012B (en) * 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
UA88879C2 (en) * 2003-09-02 2009-12-10 Эплайд Рисерч Системз Эрс Холдинг Н.В. Fsh glycosylation mutant
JP2008504012A (en) * 2004-01-28 2008-02-14 シントニックス・ファーマシューティカルズ・インコーポレーテッド Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion protein for infertility treatment
US7691848B2 (en) 2005-03-02 2010-04-06 Wyeth Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists
JPWO2006095922A1 (en) * 2005-03-10 2008-08-21 京都薬品工業株式会社 Tetrahydroisoquinoline compound and pharmaceutical use thereof
BRPI0520259A2 (en) 2005-05-04 2009-09-15 Organon Nv dihydropyridine derivative compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and use of the compound
UA92007C2 (en) 2005-05-04 2010-09-27 Н.В. Органон 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives the treatment of infertility
UA92008C2 (en) 2005-05-04 2010-09-27 Н.В. Органон 4-PHENYL-5-OXO-l,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY
UA92009C2 (en) 2005-05-04 2010-09-27 Н.В. Органон 4-PHENYL-5-0X0-l,4,5,6,7,8-HEXAHYDR0QЛIN0LINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY
US7687623B2 (en) 2005-05-12 2010-03-30 Wyeth Llc Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (FSH-R) antagonists
AU2006258007A1 (en) 2005-06-09 2006-12-21 Wyeth Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
EP2018384A2 (en) * 2006-05-17 2009-01-28 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Pyrimidine low molecular weight ligands for modulating hormone receptors
EP2081905B1 (en) 2006-07-28 2012-09-12 Boehringer Ingelheim International GmbH Sulfonyl compounds which modulate the cb2 receptor
BRPI0806365B8 (en) 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc compound, use of compound, pharmaceutical composition and use of pharmaceutical composition
JP5730575B2 (en) * 2007-10-01 2015-06-10 リクスト・バイオテクノロジー，インコーポレイテッド HDAC inhibitor
JP5492092B2 (en) 2007-11-07 2014-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Compounds that modulate the CB2 receptor
TW200944523A (en) * 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
EP2326629B1 (en) 2008-07-10 2013-10-02 Boehringer Ingelheim International GmbH Sulfone compounds which modulate the cb2 receptor
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
WO2010036630A2 (en) 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
CA2749163A1 (en) * 2009-01-14 2010-07-22 The Salk Institute For Biological Studies Methods for screening and compounds that protect against amyloid diseases
WO2010096371A2 (en) 2009-02-18 2010-08-26 Boehringer Ingelheim International Gmbh Heterocyclic compounds which modulate the cb2 receptor
TWI461426B (en) * 2009-05-27 2014-11-21 Merck Sharp & Dohme (dihydro)imidazoiso[5,1-a]quinolines
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP5756800B2 (en) * 2009-06-16 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Azetidine 2-carboxamide derivative that modulates CB2 receptor
US8431564B2 (en) 2009-07-29 2013-04-30 Merck Sharp & Dohme B.V. Ring-annulated dihydropyrrolo[2,1-α]isoquinolines
TW201116531A (en) 2009-07-29 2011-05-16 Organon Nv Ring-annulated dihydropyrrolo[2,1-a]isoquinolines
TW201116515A (en) 2009-07-31 2011-05-16 Organon Nv Dihydrobenzoindazoles
CA2772618C (en) 2009-09-01 2018-08-21 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
JP2013505295A (en) 2009-09-22 2013-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Compound that selectively modulates CB2 receptor
US9315454B2 (en) 2010-01-15 2016-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
EP2542539B1 (en) 2010-03-05 2014-02-26 Boehringer Ingelheim International GmbH Tetrazole compounds which selectively modulate the cb2 receptor
JP5746764B2 (en) 2010-07-22 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Compounds that modulate the CB2 receptor
CA2837524C (en) 2011-07-01 2019-08-20 Merck Patent Gmbh Dihydropyrazoles
EP2734517B1 (en) 2011-07-18 2017-08-30 Merck Patent GmbH Benzamides
WO2013106409A1 (en) 2012-01-10 2013-07-18 Merck Patent Gmbh Benzamide derivatives as modulators of the follicle stimulating hormone
EP2812320B1 (en) 2012-02-08 2018-03-07 Merck Patent GmbH Deuterated thiazolidinone analogues as agonists for follicle stimulating hormone receptor
KR20160004299A (en) 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 Formulations of oxabicycloheptanes and oxabicycloheptenes
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
WO2014209980A1 (en) 2013-06-24 2014-12-31 Merck Patent Gmbh Pyrazole compounds as modulators of fshr and uses thereof
JP6523267B2 (en) 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Imidazole compound as regulator of FSHR and use thereof
US11433047B2 (en) * 2015-10-09 2022-09-06 Neurotheryx Canada Ltd. Pharmaceutical compositions comprising one or more pyrone compounds, and their use for treating inflammatory and neurodegenerative diseases
EP4324477A3 (en) 2016-12-08 2024-05-22 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
US10729689B2 (en) * 2017-10-26 2020-08-04 University Of Puerto Rico Carbazole EHop-016 derivatives as anti-cancer and anti-migratory agents
CA3157525A1 (en) 2019-10-25 2021-04-29 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2021154796A1 (en) 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
WO2022192430A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
PH12023552860A1 (en) 2021-04-21 2024-05-20 Gilead Sciences Inc Carboxy-benzimidazole glp-1r modulating compounds
EP4676591A2 (en) 2023-03-08 2026-01-14 Ferring B.V. Small molecule fsh receptor modulators
CN117510475A (en) * 2023-11-01 2024-02-06 江苏缘龙医院管理有限责任公司 Musashi protein inhibitors that interfere with RNA-protein interactions and their applications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071836A (en) * 1988-12-14 1991-12-10 Hoechst Aktiengesellschaft Competitive gonadoliberin antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947569A (en) * 1972-04-12 1976-03-30 American Home Products Corporation Process for preparing the releasing hormone of luteinizing hormone (LH) and of follicle stimulating hormone (FSH), salts and compositions thereof, and intermediates therefor
JPS5331669A (en) * 1976-09-06 1978-03-25 Kissei Pharmaceut Co Ltd Novel n-acylpiperidinecaroxyanilide derivatives and their preparation
DE3636278A1 (en) * 1986-10-24 1988-05-05 Hoechst Ag HERBICIDES BASED ON CYCLIC (ALPHA) -IMINOCARBON ACID ANILIDES AND NEW (ALPHA) -IMINOCARBONIC ACID ANILIDES AND METHOD FOR THE PRODUCTION THEREOF
US4800432A (en) * 1986-10-24 1989-01-24 The Grass Valley Group, Inc. Video Difference key generator
US5071823A (en) 1988-10-12 1991-12-10 Mitsubishi Paper Mills Limited Image-receiving sheet for transfer recording
DE59309867D1 (en) * 1992-09-03 1999-12-16 Boehringer Ingelheim Pharma NEW AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
US5455229A (en) * 1992-12-23 1995-10-03 Eli Lilly And Company Method for minimizing and containing ischemic and reperfusion injury
PE45195A1 (en) * 1994-03-03 1996-01-17 Boehringer Ingelheim Kg DERIVATIVE OF AMINO ACID, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS IT
CA2322444A1 (en) * 1998-03-05 1999-09-10 Agouron Pharmaceuticals, Inc. Non-peptide gnrh agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071836A (en) * 1988-12-14 1991-12-10 Hoechst Aktiengesellschaft Competitive gonadoliberin antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071587B2 (en) 2009-05-27 2011-12-06 N. V. Organon (Dihydro)imidazoiso[5,1-A]quinolines

Also Published As

Publication number Publication date
DE69931975T2 (en) 2006-10-05
IL141063A0 (en) 2002-02-10
US6235755B1 (en) 2001-05-22
ATE279407T1 (en) 2004-10-15
US6423723B1 (en) 2002-07-23
WO2000008015A2 (en) 2000-02-17
EP1102763B1 (en) 2004-10-13
AU772373B2 (en) 2004-04-22
US20020147345A1 (en) 2002-10-10
AR021755A1 (en) 2002-08-07
IL141063A (en) 2005-06-19
CA2339018A1 (en) 2000-02-17
EP1102763A2 (en) 2001-05-30
DE69931975D1 (en) 2006-07-27
PT1102763E (en) 2005-01-31
ES2261844T3 (en) 2006-11-16
DE69921147D1 (en) 2004-11-18
AU5393199A (en) 2000-02-28
JP2002522433A (en) 2002-07-23
PT1380582E (en) 2006-08-31
ES2228084T3 (en) 2005-04-01
ATE329911T1 (en) 2006-07-15
DE69921147T2 (en) 2005-02-24
US6653338B2 (en) 2003-11-25
JP4511042B2 (en) 2010-07-28

Similar Documents

Publication Publication Date Title
WO2000008015A3 (en) Fsh mimetics for the treatment of infertility
GB2288732B (en) Pharmaceutical compositions
IL127918A0 (en) Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
MX9707431A (en) Protein kinase c inhibitors.
AP2000001996A0 (en) Heterocyclic inhibitors of P38.
MXPA04001524A (en) Rapamycin 29-enols.
BR9811956B1 (en) naphthyridinones and pharmaceutical composition comprising them.
PL339745A1 (en) Agonists of apolipoprotein a-1 and their application in treating dislipidemic disorders
TR199903331T2 (en) Farnesil protein transferase inhibitors.
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
MXPA05002814A (en) Formulation for lipophilic agents.
ZA975443B (en) Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides.
GB2352395A (en) Paroxetine methanesulfonate
PT804252E (en) METALLIC CHELTER AGENTS THAT CONTAINS DIAMOND MONOAMINES AND THIOIS
HUT73807A (en) 5-ht1-like indole derivatives and pharmaceutical compositions containing them
YU13301A (en) Muscarinic agonists and antagonists
SI1546127T1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2002070464A3 (en) Hydrazones and their therapeutic use
EP1032556A4 (en) Pharmaceutically active compounds and methods of use
AU6469401A (en) Pharmaceutically active compounds and methods of use
CA2388910A1 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
MXPA02000330A (en) Neurotrophic pyrrolidines and piperidines, and related compositions and methods.
NZ240481A (en) Aminosulphonyl urea derivatives and pharmaceutical compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 141063

Country of ref document: IL

Ref document number: 53931/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2339018

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2339018

WWE Wipo information: entry into national phase

Ref document number: 1999939686

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999939686

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 53931/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999939686

Country of ref document: EP